Inventiva S.A.
Inventiva S.A. (IVA) Stock Competitors & Peer Comparison
See (IVA) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| IVA | $3.67 | +4.26% | 190.8M | -1.02 | -$3.59 | N/A |
| VRTX | $387.77 | +3.55% | 99.4B | 27.54 | $14.08 | N/A |
| REGN | $556.55 | +1.94% | 58B | 14.02 | $39.69 | +0.32% |
| ALNY | $429.93 | -1.17% | 56.4B | -174.77 | -$2.46 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| ARGX | $637.56 | -0.21% | 39B | 32.43 | $19.66 | N/A |
| BNTX | $111.00 | +1.59% | 26.7B | -66.87 | -$1.66 | N/A |
| BGNE | $184.71 | +0.49% | 20.2B | -22.55 | -$8.19 | N/A |
| SMMT | $25.69 | -9.06% | 19.1B | -75.54 | -$0.34 | N/A |
| DNA-WT | $0.27 | -2.76% | 18.7B | N/A | N/A | N/A |
Stock Comparison
IVA vs VRTX Comparison August 2025
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 190.8M. In comparison, VRTX has a market cap of 99.4B. Regarding current trading prices, IVA is priced at $3.67, while VRTX trades at $387.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.02, whereas VRTX's P/E ratio is 27.54. In terms of profitability, IVA's ROE is +1.98%, compared to VRTX's ROE of +0.22%. Regarding short-term risk, IVA is more volatile compared to VRTX. This indicates potentially higher risk in terms of short-term price fluctuations for IVA.Check VRTX's competition here
IVA vs REGN Comparison August 2025
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 190.8M. In comparison, REGN has a market cap of 58B. Regarding current trading prices, IVA is priced at $3.67, while REGN trades at $556.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.02, whereas REGN's P/E ratio is 14.02. In terms of profitability, IVA's ROE is +1.98%, compared to REGN's ROE of +0.15%. Regarding short-term risk, IVA is more volatile compared to REGN. This indicates potentially higher risk in terms of short-term price fluctuations for IVA.Check REGN's competition here
IVA vs ALNY Comparison August 2025
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 190.8M. In comparison, ALNY has a market cap of 56.4B. Regarding current trading prices, IVA is priced at $3.67, while ALNY trades at $429.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.02, whereas ALNY's P/E ratio is -174.77. In terms of profitability, IVA's ROE is +1.98%, compared to ALNY's ROE of -2.74%. Regarding short-term risk, IVA is more volatile compared to ALNY. This indicates potentially higher risk in terms of short-term price fluctuations for IVA.Check ALNY's competition here
IVA vs SGEN Comparison August 2025
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 190.8M. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, IVA is priced at $3.67, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.02, whereas SGEN's P/E ratio is -57.19. In terms of profitability, IVA's ROE is +1.98%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, IVA is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for IVA.Check SGEN's competition here
IVA vs ARGX Comparison August 2025
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 190.8M. In comparison, ARGX has a market cap of 39B. Regarding current trading prices, IVA is priced at $3.67, while ARGX trades at $637.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.02, whereas ARGX's P/E ratio is 32.43. In terms of profitability, IVA's ROE is +1.98%, compared to ARGX's ROE of +0.26%. Regarding short-term risk, IVA is more volatile compared to ARGX. This indicates potentially higher risk in terms of short-term price fluctuations for IVA.Check ARGX's competition here
IVA vs BNTX Comparison August 2025
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 190.8M. In comparison, BNTX has a market cap of 26.7B. Regarding current trading prices, IVA is priced at $3.67, while BNTX trades at $111.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.02, whereas BNTX's P/E ratio is -66.87. In terms of profitability, IVA's ROE is +1.98%, compared to BNTX's ROE of -0.02%. Regarding short-term risk, IVA is more volatile compared to BNTX. This indicates potentially higher risk in terms of short-term price fluctuations for IVA.Check BNTX's competition here
IVA vs BGNE Comparison August 2025
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 190.8M. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, IVA is priced at $3.67, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.02, whereas BGNE's P/E ratio is -22.55. In terms of profitability, IVA's ROE is +1.98%, compared to BGNE's ROE of -0.12%. Regarding short-term risk, IVA is more volatile compared to BGNE. This indicates potentially higher risk in terms of short-term price fluctuations for IVA.Check BGNE's competition here
IVA vs SMMT Comparison August 2025
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 190.8M. In comparison, SMMT has a market cap of 19.1B. Regarding current trading prices, IVA is priced at $3.67, while SMMT trades at $25.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.02, whereas SMMT's P/E ratio is -75.54. In terms of profitability, IVA's ROE is +1.98%, compared to SMMT's ROE of -2.09%. Regarding short-term risk, IVA is less volatile compared to SMMT. This indicates potentially lower risk in terms of short-term price fluctuations for IVA.Check SMMT's competition here
IVA vs DNA-WT Comparison August 2025
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 190.8M. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, IVA is priced at $3.67, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.02, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, IVA's ROE is +1.98%, compared to DNA-WT's ROE of -0.45%. Regarding short-term risk, IVA is less volatile compared to DNA-WT. This indicates potentially lower risk in terms of short-term price fluctuations for IVA.Check DNA-WT's competition here
IVA vs INCY Comparison August 2025
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 190.8M. In comparison, INCY has a market cap of 15.9B. Regarding current trading prices, IVA is priced at $3.67, while INCY trades at $81.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.02, whereas INCY's P/E ratio is 19.29. In terms of profitability, IVA's ROE is +1.98%, compared to INCY's ROE of +0.34%. Regarding short-term risk, IVA is more volatile compared to INCY. This indicates potentially higher risk in terms of short-term price fluctuations for IVA.Check INCY's competition here
IVA vs RPRX Comparison August 2025
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 190.8M. In comparison, RPRX has a market cap of 15.1B. Regarding current trading prices, IVA is priced at $3.67, while RPRX trades at $35.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.02, whereas RPRX's P/E ratio is 15.66. In terms of profitability, IVA's ROE is +1.98%, compared to RPRX's ROE of +0.15%. Regarding short-term risk, IVA is more volatile compared to RPRX. This indicates potentially higher risk in terms of short-term price fluctuations for IVA.Check RPRX's competition here
IVA vs GMAB Comparison August 2025
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 190.8M. In comparison, GMAB has a market cap of 13.8B. Regarding current trading prices, IVA is priced at $3.67, while GMAB trades at $21.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.02, whereas GMAB's P/E ratio is 11.33. In terms of profitability, IVA's ROE is +1.98%, compared to GMAB's ROE of +0.26%. Regarding short-term risk, IVA is more volatile compared to GMAB. This indicates potentially higher risk in terms of short-term price fluctuations for IVA.Check GMAB's competition here
IVA vs UTHR Comparison August 2025
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 190.8M. In comparison, UTHR has a market cap of 13.6B. Regarding current trading prices, IVA is priced at $3.67, while UTHR trades at $301.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.02, whereas UTHR's P/E ratio is 11.76. In terms of profitability, IVA's ROE is +1.98%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, IVA is more volatile compared to UTHR. This indicates potentially higher risk in terms of short-term price fluctuations for IVA.Check UTHR's competition here
IVA vs KRTX Comparison August 2025
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 190.8M. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, IVA is priced at $3.67, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.02, whereas KRTX's P/E ratio is -28.09. In terms of profitability, IVA's ROE is +1.98%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, IVA is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for IVA.Check KRTX's competition here
IVA vs ASND Comparison August 2025
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 190.8M. In comparison, ASND has a market cap of 11.9B. Regarding current trading prices, IVA is priced at $3.67, while ASND trades at $195.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.02, whereas ASND's P/E ratio is -37.01. In terms of profitability, IVA's ROE is +1.98%, compared to ASND's ROE of +1.91%. Regarding short-term risk, IVA is less volatile compared to ASND. This indicates potentially lower risk in terms of short-term price fluctuations for IVA.Check ASND's competition here
IVA vs BMRN Comparison August 2025
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 190.8M. In comparison, BMRN has a market cap of 10.9B. Regarding current trading prices, IVA is priced at $3.67, while BMRN trades at $56.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.02, whereas BMRN's P/E ratio is 16.77. In terms of profitability, IVA's ROE is +1.98%, compared to BMRN's ROE of +0.11%. Regarding short-term risk, IVA is more volatile compared to BMRN. This indicates potentially higher risk in terms of short-term price fluctuations for IVA.Check BMRN's competition here
IVA vs EXEL Comparison August 2025
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 190.8M. In comparison, EXEL has a market cap of 10.2B. Regarding current trading prices, IVA is priced at $3.67, while EXEL trades at $37.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.02, whereas EXEL's P/E ratio is 18.25. In terms of profitability, IVA's ROE is +1.98%, compared to EXEL's ROE of +0.28%. Regarding short-term risk, IVA is more volatile compared to EXEL. This indicates potentially higher risk in terms of short-term price fluctuations for IVA.Check EXEL's competition here
IVA vs MRNA Comparison August 2025
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 190.8M. In comparison, MRNA has a market cap of 10B. Regarding current trading prices, IVA is priced at $3.67, while MRNA trades at $25.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.02, whereas MRNA's P/E ratio is -3.42. In terms of profitability, IVA's ROE is +1.98%, compared to MRNA's ROE of -0.27%. Regarding short-term risk, IVA is less volatile compared to MRNA. This indicates potentially lower risk in terms of short-term price fluctuations for IVA.Check MRNA's competition here
IVA vs RXDX Comparison August 2025
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 190.8M. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, IVA is priced at $3.67, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.02, whereas RXDX's P/E ratio is -56.47. In terms of profitability, IVA's ROE is +1.98%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, IVA is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for IVA.Check RXDX's competition here
IVA vs BBIO Comparison August 2025
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 190.8M. In comparison, BBIO has a market cap of 9.4B. Regarding current trading prices, IVA is priced at $3.67, while BBIO trades at $49.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.02, whereas BBIO's P/E ratio is -11.89. In terms of profitability, IVA's ROE is +1.98%, compared to BBIO's ROE of +0.51%. Regarding short-term risk, IVA is less volatile compared to BBIO. This indicates potentially lower risk in terms of short-term price fluctuations for IVA.Check BBIO's competition here
IVA vs VRNA Comparison August 2025
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 190.8M. In comparison, VRNA has a market cap of 8.9B. Regarding current trading prices, IVA is priced at $3.67, while VRNA trades at $105.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.02, whereas VRNA's P/E ratio is -101.14. In terms of profitability, IVA's ROE is +1.98%, compared to VRNA's ROE of -0.90%. Regarding short-term risk, IVA is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for IVA.Check VRNA's competition here
IVA vs IMGN Comparison August 2025
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 190.8M. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, IVA is priced at $3.67, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.02, whereas IMGN's P/E ratio is -111.55. In terms of profitability, IVA's ROE is +1.98%, compared to IMGN's ROE of -1.43%. Regarding short-term risk, IVA is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for IVA.Check IMGN's competition here
IVA vs BPMC Comparison August 2025
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 190.8M. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, IVA is priced at $3.67, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.02, whereas BPMC's P/E ratio is -51.58. In terms of profitability, IVA's ROE is +1.98%, compared to BPMC's ROE of -0.49%. Regarding short-term risk, IVA is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for IVA.Check BPMC's competition here
IVA vs TECH Comparison August 2025
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 190.8M. In comparison, TECH has a market cap of 8.3B. Regarding current trading prices, IVA is priced at $3.67, while TECH trades at $52.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.02, whereas TECH's P/E ratio is 114.85. In terms of profitability, IVA's ROE is +1.98%, compared to TECH's ROE of +0.06%. Regarding short-term risk, IVA is less volatile compared to TECH. This indicates potentially lower risk in terms of short-term price fluctuations for IVA.Check TECH's competition here
IVA vs CERE Comparison August 2025
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 190.8M. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, IVA is priced at $3.67, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.02, whereas CERE's P/E ratio is -16.47. In terms of profitability, IVA's ROE is +1.98%, compared to CERE's ROE of -0.72%. Regarding short-term risk, IVA is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for IVA.Check CERE's competition here
IVA vs MDGL Comparison August 2025
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 190.8M. In comparison, MDGL has a market cap of 8B. Regarding current trading prices, IVA is priced at $3.67, while MDGL trades at $359.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.02, whereas MDGL's P/E ratio is -28.38. In terms of profitability, IVA's ROE is +1.98%, compared to MDGL's ROE of -0.38%. Regarding short-term risk, IVA is more volatile compared to MDGL. This indicates potentially higher risk in terms of short-term price fluctuations for IVA.Check MDGL's competition here
IVA vs ROIV Comparison August 2025
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 190.8M. In comparison, ROIV has a market cap of 7.9B. Regarding current trading prices, IVA is priced at $3.67, while ROIV trades at $11.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.02, whereas ROIV's P/E ratio is -10.61. In terms of profitability, IVA's ROE is +1.98%, compared to ROIV's ROE of -0.03%. Regarding short-term risk, IVA is less volatile compared to ROIV. This indicates potentially lower risk in terms of short-term price fluctuations for IVA.Check ROIV's competition here
IVA vs ROIVW Comparison August 2025
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 190.8M. In comparison, ROIVW has a market cap of 7.8B. Regarding current trading prices, IVA is priced at $3.67, while ROIVW trades at $2.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.02, whereas ROIVW's P/E ratio is -0.67. In terms of profitability, IVA's ROE is +1.98%, compared to ROIVW's ROE of -0.03%. Regarding short-term risk, IVA is less volatile compared to ROIVW. This indicates potentially lower risk in terms of short-term price fluctuations for IVA.Check ROIVW's competition here
IVA vs CORT Comparison August 2025
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 190.8M. In comparison, CORT has a market cap of 7.8B. Regarding current trading prices, IVA is priced at $3.67, while CORT trades at $73.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.02, whereas CORT's P/E ratio is 65.71. In terms of profitability, IVA's ROE is +1.98%, compared to CORT's ROE of +0.20%. Regarding short-term risk, IVA is less volatile compared to CORT. This indicates potentially lower risk in terms of short-term price fluctuations for IVA.Check CORT's competition here
IVA vs HALO Comparison August 2025
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 190.8M. In comparison, HALO has a market cap of 7.5B. Regarding current trading prices, IVA is priced at $3.67, while HALO trades at $64.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.02, whereas HALO's P/E ratio is 14.65. In terms of profitability, IVA's ROE is +1.98%, compared to HALO's ROE of +1.37%. Regarding short-term risk, IVA is more volatile compared to HALO. This indicates potentially higher risk in terms of short-term price fluctuations for IVA.Check HALO's competition here
IVA vs JAZZ Comparison August 2025
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 190.8M. In comparison, JAZZ has a market cap of 6.9B. Regarding current trading prices, IVA is priced at $3.67, while JAZZ trades at $113.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.02, whereas JAZZ's P/E ratio is -16.24. In terms of profitability, IVA's ROE is +1.98%, compared to JAZZ's ROE of -0.10%. Regarding short-term risk, IVA is more volatile compared to JAZZ. This indicates potentially higher risk in terms of short-term price fluctuations for IVA.Check JAZZ's competition here
IVA vs IONS Comparison August 2025
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 190.8M. In comparison, IONS has a market cap of 6.6B. Regarding current trading prices, IVA is priced at $3.67, while IONS trades at $41.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.02, whereas IONS's P/E ratio is -23.53. In terms of profitability, IVA's ROE is +1.98%, compared to IONS's ROE of -0.45%. Regarding short-term risk, IVA is more volatile compared to IONS. This indicates potentially higher risk in terms of short-term price fluctuations for IVA.Check IONS's competition here
IVA vs RVMD Comparison August 2025
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 190.8M. In comparison, RVMD has a market cap of 6.6B. Regarding current trading prices, IVA is priced at $3.67, while RVMD trades at $35.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.02, whereas RVMD's P/E ratio is -7.80. In terms of profitability, IVA's ROE is +1.98%, compared to RVMD's ROE of -0.39%. Regarding short-term risk, IVA is less volatile compared to RVMD. This indicates potentially lower risk in terms of short-term price fluctuations for IVA.Check RVMD's competition here
IVA vs RETA Comparison August 2025
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 190.8M. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, IVA is priced at $3.67, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.02, whereas RETA's P/E ratio is -66.29. In terms of profitability, IVA's ROE is +1.98%, compared to RETA's ROE of +0.47%. Regarding short-term risk, IVA is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for IVA.Check RETA's competition here
IVA vs RYTM Comparison August 2025
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 190.8M. In comparison, RYTM has a market cap of 6.4B. Regarding current trading prices, IVA is priced at $3.67, while RYTM trades at $96.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.02, whereas RYTM's P/E ratio is -32.05. In terms of profitability, IVA's ROE is +1.98%, compared to RYTM's ROE of -1.55%. Regarding short-term risk, IVA is more volatile compared to RYTM. This indicates potentially higher risk in terms of short-term price fluctuations for IVA.Check RYTM's competition here
IVA vs RNA Comparison August 2025
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 190.8M. In comparison, RNA has a market cap of 5.9B. Regarding current trading prices, IVA is priced at $3.67, while RNA trades at $46.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.02, whereas RNA's P/E ratio is -12.99. In terms of profitability, IVA's ROE is +1.98%, compared to RNA's ROE of -0.33%. Regarding short-term risk, IVA is more volatile compared to RNA. This indicates potentially higher risk in terms of short-term price fluctuations for IVA.Check RNA's competition here
IVA vs ABCM Comparison August 2025
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 190.8M. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, IVA is priced at $3.67, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.02, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, IVA's ROE is +1.98%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, IVA is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for IVA.Check ABCM's competition here
IVA vs ISEE Comparison August 2025
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 190.8M. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, IVA is priced at $3.67, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.02, whereas ISEE's P/E ratio is -22.44. In terms of profitability, IVA's ROE is +1.98%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, IVA is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for IVA.Check ISEE's competition here
IVA vs NUVL Comparison August 2025
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 190.8M. In comparison, NUVL has a market cap of 5.5B. Regarding current trading prices, IVA is priced at $3.67, while NUVL trades at $76.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.02, whereas NUVL's P/E ratio is -15.57. In terms of profitability, IVA's ROE is +1.98%, compared to NUVL's ROE of -0.33%. Regarding short-term risk, IVA is more volatile compared to NUVL. This indicates potentially higher risk in terms of short-term price fluctuations for IVA.Check NUVL's competition here
IVA vs ABVX Comparison August 2025
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 190.8M. In comparison, ABVX has a market cap of 5.4B. Regarding current trading prices, IVA is priced at $3.67, while ABVX trades at $71.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.02, whereas ABVX's P/E ratio is -20.90. In terms of profitability, IVA's ROE is +1.98%, compared to ABVX's ROE of -1.06%. Regarding short-term risk, IVA is less volatile compared to ABVX. This indicates potentially lower risk in terms of short-term price fluctuations for IVA.Check ABVX's competition here
IVA vs AXSM Comparison August 2025
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 190.8M. In comparison, AXSM has a market cap of 5.3B. Regarding current trading prices, IVA is priced at $3.67, while AXSM trades at $105.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.02, whereas AXSM's P/E ratio is -20.80. In terms of profitability, IVA's ROE is +1.98%, compared to AXSM's ROE of -3.58%. Regarding short-term risk, IVA is more volatile compared to AXSM. This indicates potentially higher risk in terms of short-term price fluctuations for IVA.Check AXSM's competition here
IVA vs CRSP Comparison August 2025
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 190.8M. In comparison, CRSP has a market cap of 5.1B. Regarding current trading prices, IVA is priced at $3.67, while CRSP trades at $56.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.02, whereas CRSP's P/E ratio is -10.48. In terms of profitability, IVA's ROE is +1.98%, compared to CRSP's ROE of -0.25%. Regarding short-term risk, IVA is more volatile compared to CRSP. This indicates potentially higher risk in terms of short-term price fluctuations for IVA.Check CRSP's competition here
IVA vs MRUS Comparison August 2025
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 190.8M. In comparison, MRUS has a market cap of 4.8B. Regarding current trading prices, IVA is priced at $3.67, while MRUS trades at $63.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.02, whereas MRUS's P/E ratio is -11.43. In terms of profitability, IVA's ROE is +1.98%, compared to MRUS's ROE of -0.55%. Regarding short-term risk, IVA is less volatile compared to MRUS. This indicates potentially lower risk in terms of short-term price fluctuations for IVA.Check MRUS's competition here
IVA vs ALKS Comparison August 2025
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 190.8M. In comparison, ALKS has a market cap of 4.5B. Regarding current trading prices, IVA is priced at $3.67, while ALKS trades at $27.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.02, whereas ALKS's P/E ratio is 13.25. In terms of profitability, IVA's ROE is +1.98%, compared to ALKS's ROE of +0.24%. Regarding short-term risk, IVA is more volatile compared to ALKS. This indicates potentially higher risk in terms of short-term price fluctuations for IVA.Check ALKS's competition here
IVA vs VKTX Comparison August 2025
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 190.8M. In comparison, VKTX has a market cap of 4.5B. Regarding current trading prices, IVA is priced at $3.67, while VKTX trades at $39.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.02, whereas VKTX's P/E ratio is -25.88. In terms of profitability, IVA's ROE is +1.98%, compared to VKTX's ROE of -0.20%. Regarding short-term risk, IVA is less volatile compared to VKTX. This indicates potentially lower risk in terms of short-term price fluctuations for IVA.Check VKTX's competition here
IVA vs ALPN Comparison August 2025
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 190.8M. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, IVA is priced at $3.67, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.02, whereas ALPN's P/E ratio is -101.52. In terms of profitability, IVA's ROE is +1.98%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, IVA is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for IVA.Check ALPN's competition here
IVA vs SLNO Comparison August 2025
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 190.8M. In comparison, SLNO has a market cap of 4.4B. Regarding current trading prices, IVA is priced at $3.67, while SLNO trades at $83.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.02, whereas SLNO's P/E ratio is -19.75. In terms of profitability, IVA's ROE is +1.98%, compared to SLNO's ROE of -0.74%. Regarding short-term risk, IVA is less volatile compared to SLNO. This indicates potentially lower risk in terms of short-term price fluctuations for IVA.Check SLNO's competition here
IVA vs TGTX Comparison August 2025
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 190.8M. In comparison, TGTX has a market cap of 4.3B. Regarding current trading prices, IVA is priced at $3.67, while TGTX trades at $27.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.02, whereas TGTX's P/E ratio is 71.37. In terms of profitability, IVA's ROE is +1.98%, compared to TGTX's ROE of +0.29%. Regarding short-term risk, IVA is less volatile compared to TGTX. This indicates potentially lower risk in terms of short-term price fluctuations for IVA.Check TGTX's competition here
IVA vs ACAD Comparison August 2025
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 190.8M. In comparison, ACAD has a market cap of 4.3B. Regarding current trading prices, IVA is priced at $3.67, while ACAD trades at $25.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.02, whereas ACAD's P/E ratio is 19.14. In terms of profitability, IVA's ROE is +1.98%, compared to ACAD's ROE of +0.31%. Regarding short-term risk, IVA is less volatile compared to ACAD. This indicates potentially lower risk in terms of short-term price fluctuations for IVA.Check ACAD's competition here
IVA vs OPT Comparison August 2025
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 190.8M. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, IVA is priced at $3.67, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.02, whereas OPT's P/E ratio is -1.52. In terms of profitability, IVA's ROE is +1.98%, compared to OPT's ROE of +2.60%. Regarding short-term risk, IVA is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for IVA.Check OPT's competition here
IVA vs KRYS Comparison August 2025
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 190.8M. In comparison, KRYS has a market cap of 4.2B. Regarding current trading prices, IVA is priced at $3.67, while KRYS trades at $143.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.02, whereas KRYS's P/E ratio is 29.19. In terms of profitability, IVA's ROE is +1.98%, compared to KRYS's ROE of +0.15%. Regarding short-term risk, IVA is less volatile compared to KRYS. This indicates potentially lower risk in terms of short-term price fluctuations for IVA.Check KRYS's competition here
IVA vs MRTX Comparison August 2025
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 190.8M. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, IVA is priced at $3.67, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.02, whereas MRTX's P/E ratio is -4.82. In terms of profitability, IVA's ROE is +1.98%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, IVA is more volatile compared to MRTX. This indicates potentially higher risk in terms of short-term price fluctuations for IVA.Check MRTX's competition here
IVA vs CYTK Comparison August 2025
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 190.8M. In comparison, CYTK has a market cap of 4.1B. Regarding current trading prices, IVA is priced at $3.67, while CYTK trades at $34.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.02, whereas CYTK's P/E ratio is -6.70. In terms of profitability, IVA's ROE is +1.98%, compared to CYTK's ROE of +3.09%. Regarding short-term risk, IVA is less volatile compared to CYTK. This indicates potentially lower risk in terms of short-term price fluctuations for IVA.Check CYTK's competition here
IVA vs ACLX Comparison August 2025
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 190.8M. In comparison, ACLX has a market cap of 4B. Regarding current trading prices, IVA is priced at $3.67, while ACLX trades at $72.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.02, whereas ACLX's P/E ratio is -21.27. In terms of profitability, IVA's ROE is +1.98%, compared to ACLX's ROE of -0.43%. Regarding short-term risk, IVA is less volatile compared to ACLX. This indicates potentially lower risk in terms of short-term price fluctuations for IVA.Check ACLX's competition here
IVA vs ADMA Comparison August 2025
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 190.8M. In comparison, ADMA has a market cap of 4B. Regarding current trading prices, IVA is priced at $3.67, while ADMA trades at $16.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.02, whereas ADMA's P/E ratio is 19.72. In terms of profitability, IVA's ROE is +1.98%, compared to ADMA's ROE of +0.62%. Regarding short-term risk, IVA is less volatile compared to ADMA. This indicates potentially lower risk in terms of short-term price fluctuations for IVA.Check ADMA's competition here
IVA vs PCVX Comparison August 2025
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 190.8M. In comparison, PCVX has a market cap of 4B. Regarding current trading prices, IVA is priced at $3.67, while PCVX trades at $30.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.02, whereas PCVX's P/E ratio is -7.41. In terms of profitability, IVA's ROE is +1.98%, compared to PCVX's ROE of -0.17%. Regarding short-term risk, IVA is more volatile compared to PCVX. This indicates potentially higher risk in terms of short-term price fluctuations for IVA.Check PCVX's competition here
IVA vs AKRO Comparison August 2025
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 190.8M. In comparison, AKRO has a market cap of 3.8B. Regarding current trading prices, IVA is priced at $3.67, while AKRO trades at $48.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.02, whereas AKRO's P/E ratio is -12.61. In terms of profitability, IVA's ROE is +1.98%, compared to AKRO's ROE of -0.32%. Regarding short-term risk, IVA is more volatile compared to AKRO. This indicates potentially higher risk in terms of short-term price fluctuations for IVA.Check AKRO's competition here
IVA vs ZLAB Comparison August 2025
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 190.8M. In comparison, ZLAB has a market cap of 3.8B. Regarding current trading prices, IVA is priced at $3.67, while ZLAB trades at $34.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.02, whereas ZLAB's P/E ratio is -17.15. In terms of profitability, IVA's ROE is +1.98%, compared to ZLAB's ROE of -0.27%. Regarding short-term risk, IVA is more volatile compared to ZLAB. This indicates potentially higher risk in terms of short-term price fluctuations for IVA.Check ZLAB's competition here
IVA vs RYZB Comparison August 2025
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 190.8M. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, IVA is priced at $3.67, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.02, whereas RYZB's P/E ratio is -57.86. In terms of profitability, IVA's ROE is +1.98%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, IVA is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for IVA.Check RYZB's competition here
IVA vs CBAY Comparison August 2025
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 190.8M. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, IVA is priced at $3.67, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.02, whereas CBAY's P/E ratio is -32.81. In terms of profitability, IVA's ROE is +1.98%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, IVA is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for IVA.Check CBAY's competition here
IVA vs AAPG Comparison August 2025
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 190.8M. In comparison, AAPG has a market cap of 3.7B. Regarding current trading prices, IVA is priced at $3.67, while AAPG trades at $40.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.02, whereas AAPG's P/E ratio is -54.12. In terms of profitability, IVA's ROE is +1.98%, compared to AAPG's ROE of -2.50%. Regarding short-term risk, IVA is more volatile compared to AAPG. This indicates potentially higher risk in terms of short-term price fluctuations for IVA.Check AAPG's competition here
IVA vs TLX Comparison August 2025
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 190.8M. In comparison, TLX has a market cap of 3.7B. Regarding current trading prices, IVA is priced at $3.67, while TLX trades at $10.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.02, whereas TLX's P/E ratio is 120.22. In terms of profitability, IVA's ROE is +1.98%, compared to TLX's ROE of +0.10%. Regarding short-term risk, IVA is more volatile compared to TLX. This indicates potentially higher risk in terms of short-term price fluctuations for IVA.Check TLX's competition here
IVA vs PTCT Comparison August 2025
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 190.8M. In comparison, PTCT has a market cap of 3.6B. Regarding current trading prices, IVA is priced at $3.67, while PTCT trades at $45.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.02, whereas PTCT's P/E ratio is 6.42. In terms of profitability, IVA's ROE is +1.98%, compared to PTCT's ROE of -0.99%. Regarding short-term risk, IVA is less volatile compared to PTCT. This indicates potentially lower risk in terms of short-term price fluctuations for IVA.Check PTCT's competition here
IVA vs SWTX Comparison August 2025
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 190.8M. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, IVA is priced at $3.67, while SWTX trades at $46.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.02, whereas SWTX's P/E ratio is -13.78. In terms of profitability, IVA's ROE is +1.98%, compared to SWTX's ROE of -0.51%. Regarding short-term risk, IVA is more volatile compared to SWTX. This indicates potentially higher risk in terms of short-term price fluctuations for IVA.Check SWTX's competition here
IVA vs MLTX Comparison August 2025
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 190.8M. In comparison, MLTX has a market cap of 3.5B. Regarding current trading prices, IVA is priced at $3.67, while MLTX trades at $54.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.02, whereas MLTX's P/E ratio is -19.66. In terms of profitability, IVA's ROE is +1.98%, compared to MLTX's ROE of -0.42%. Regarding short-term risk, IVA is more volatile compared to MLTX. This indicates potentially higher risk in terms of short-term price fluctuations for IVA.Check MLTX's competition here
IVA vs LEGN Comparison August 2025
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 190.8M. In comparison, LEGN has a market cap of 3.4B. Regarding current trading prices, IVA is priced at $3.67, while LEGN trades at $36.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.02, whereas LEGN's P/E ratio is -31.35. In terms of profitability, IVA's ROE is +1.98%, compared to LEGN's ROE of -0.31%. Regarding short-term risk, IVA is less volatile compared to LEGN. This indicates potentially lower risk in terms of short-term price fluctuations for IVA.Check LEGN's competition here
IVA vs PTGX Comparison August 2025
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 190.8M. In comparison, PTGX has a market cap of 3.4B. Regarding current trading prices, IVA is priced at $3.67, while PTGX trades at $54.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.02, whereas PTGX's P/E ratio is 74.70. In terms of profitability, IVA's ROE is +1.98%, compared to PTGX's ROE of +0.08%. Regarding short-term risk, IVA is more volatile compared to PTGX. This indicates potentially higher risk in terms of short-term price fluctuations for IVA.Check PTGX's competition here
IVA vs MIRM Comparison August 2025
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 190.8M. In comparison, MIRM has a market cap of 3.3B. Regarding current trading prices, IVA is priced at $3.67, while MIRM trades at $64.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.02, whereas MIRM's P/E ratio is -53.49. In terms of profitability, IVA's ROE is +1.98%, compared to MIRM's ROE of -0.25%. Regarding short-term risk, IVA is less volatile compared to MIRM. This indicates potentially lower risk in terms of short-term price fluctuations for IVA.Check MIRM's competition here
IVA vs MTSR Comparison August 2025
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 190.8M. In comparison, MTSR has a market cap of 3.2B. Regarding current trading prices, IVA is priced at $3.67, while MTSR trades at $30.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.02, whereas MTSR's P/E ratio is -10.47. In terms of profitability, IVA's ROE is +1.98%, compared to MTSR's ROE of -0.90%. Regarding short-term risk, IVA is less volatile compared to MTSR. This indicates potentially lower risk in terms of short-term price fluctuations for IVA.Check MTSR's competition here
IVA vs SRRK Comparison August 2025
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 190.8M. In comparison, SRRK has a market cap of 3.1B. Regarding current trading prices, IVA is priced at $3.67, while SRRK trades at $32.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.02, whereas SRRK's P/E ratio is -11.03. In terms of profitability, IVA's ROE is +1.98%, compared to SRRK's ROE of -1.27%. Regarding short-term risk, IVA is more volatile compared to SRRK. This indicates potentially higher risk in terms of short-term price fluctuations for IVA.Check SRRK's competition here
IVA vs APLS Comparison August 2025
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 190.8M. In comparison, APLS has a market cap of 3B. Regarding current trading prices, IVA is priced at $3.67, while APLS trades at $23.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.02, whereas APLS's P/E ratio is -13.06. In terms of profitability, IVA's ROE is +1.98%, compared to APLS's ROE of -1.16%. Regarding short-term risk, IVA is more volatile compared to APLS. This indicates potentially higher risk in terms of short-term price fluctuations for IVA.Check APLS's competition here
IVA vs LGND Comparison August 2025
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 190.8M. In comparison, LGND has a market cap of 3B. Regarding current trading prices, IVA is priced at $3.67, while LGND trades at $152.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.02, whereas LGND's P/E ratio is -37.89. In terms of profitability, IVA's ROE is +1.98%, compared to LGND's ROE of -0.09%. Regarding short-term risk, IVA is less volatile compared to LGND. This indicates potentially lower risk in terms of short-term price fluctuations for IVA.Check LGND's competition here
IVA vs MORF Comparison August 2025
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 190.8M. In comparison, MORF has a market cap of 2.9B. Regarding current trading prices, IVA is priced at $3.67, while MORF trades at $56.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.02, whereas MORF's P/E ratio is -14.88. In terms of profitability, IVA's ROE is +1.98%, compared to MORF's ROE of -0.16%. Regarding short-term risk, IVA is more volatile compared to MORF. This indicates potentially higher risk in terms of short-term price fluctuations for IVA.Check MORF's competition here
IVA vs MOR Comparison August 2025
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 190.8M. In comparison, MOR has a market cap of 2.9B. Regarding current trading prices, IVA is priced at $3.67, while MOR trades at $18.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.02, whereas MOR's P/E ratio is -12.64. In terms of profitability, IVA's ROE is +1.98%, compared to MOR's ROE of -1.84%. Regarding short-term risk, IVA is less volatile compared to MOR. This indicates potentially lower risk in terms of short-term price fluctuations for IVA.Check MOR's competition here
IVA vs NAMS Comparison August 2025
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 190.8M. In comparison, NAMS has a market cap of 2.8B. Regarding current trading prices, IVA is priced at $3.67, while NAMS trades at $25.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.02, whereas NAMS's P/E ratio is -15.72. In terms of profitability, IVA's ROE is +1.98%, compared to NAMS's ROE of -0.25%. Regarding short-term risk, IVA is less volatile compared to NAMS. This indicates potentially lower risk in terms of short-term price fluctuations for IVA.Check NAMS's competition here
IVA vs KYMR Comparison August 2025
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 190.8M. In comparison, KYMR has a market cap of 2.8B. Regarding current trading prices, IVA is priced at $3.67, while KYMR trades at $39.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.02, whereas KYMR's P/E ratio is -11.42. In terms of profitability, IVA's ROE is +1.98%, compared to KYMR's ROE of -0.32%. Regarding short-term risk, IVA is less volatile compared to KYMR. This indicates potentially lower risk in terms of short-term price fluctuations for IVA.Check KYMR's competition here
IVA vs XENE Comparison August 2025
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 190.8M. In comparison, XENE has a market cap of 2.8B. Regarding current trading prices, IVA is priced at $3.67, while XENE trades at $35.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.02, whereas XENE's P/E ratio is -11.18. In terms of profitability, IVA's ROE is +1.98%, compared to XENE's ROE of -0.32%. Regarding short-term risk, IVA is less volatile compared to XENE. This indicates potentially lower risk in terms of short-term price fluctuations for IVA.Check XENE's competition here
IVA vs RARE Comparison August 2025
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 190.8M. In comparison, RARE has a market cap of 2.7B. Regarding current trading prices, IVA is priced at $3.67, while RARE trades at $28.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.02, whereas RARE's P/E ratio is -5.13. In terms of profitability, IVA's ROE is +1.98%, compared to RARE's ROE of -2.37%. Regarding short-term risk, IVA is more volatile compared to RARE. This indicates potentially higher risk in terms of short-term price fluctuations for IVA.Check RARE's competition here
IVA vs KDNY Comparison August 2025
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 190.8M. In comparison, KDNY has a market cap of 2.7B. Regarding current trading prices, IVA is priced at $3.67, while KDNY trades at $40.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.02, whereas KDNY's P/E ratio is -12.47. In terms of profitability, IVA's ROE is +1.98%, compared to KDNY's ROE of -0.41%. Regarding short-term risk, IVA is more volatile compared to KDNY. This indicates potentially higher risk in terms of short-term price fluctuations for IVA.Check KDNY's competition here
IVA vs CRNX Comparison August 2025
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 190.8M. In comparison, CRNX has a market cap of 2.7B. Regarding current trading prices, IVA is priced at $3.67, while CRNX trades at $28.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.02, whereas CRNX's P/E ratio is -6.95. In terms of profitability, IVA's ROE is +1.98%, compared to CRNX's ROE of -0.32%. Regarding short-term risk, IVA is less volatile compared to CRNX. This indicates potentially lower risk in terms of short-term price fluctuations for IVA.Check CRNX's competition here
IVA vs MYOV Comparison August 2025
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 190.8M. In comparison, MYOV has a market cap of 2.6B. Regarding current trading prices, IVA is priced at $3.67, while MYOV trades at $26.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.02, whereas MYOV's P/E ratio is -14.05. In terms of profitability, IVA's ROE is +1.98%, compared to MYOV's ROE of +0.50%. Regarding short-term risk, IVA is more volatile compared to MYOV. This indicates potentially higher risk in terms of short-term price fluctuations for IVA.Check MYOV's competition here
IVA vs IMVT Comparison August 2025
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 190.8M. In comparison, IMVT has a market cap of 2.6B. Regarding current trading prices, IVA is priced at $3.67, while IMVT trades at $15.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.02, whereas IMVT's P/E ratio is -5.57. In terms of profitability, IVA's ROE is +1.98%, compared to IMVT's ROE of -0.84%. Regarding short-term risk, IVA is less volatile compared to IMVT. This indicates potentially lower risk in terms of short-term price fluctuations for IVA.Check IMVT's competition here
IVA vs CPRX Comparison August 2025
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 190.8M. In comparison, CPRX has a market cap of 2.5B. Regarding current trading prices, IVA is priced at $3.67, while CPRX trades at $20.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.02, whereas CPRX's P/E ratio is 12.33. In terms of profitability, IVA's ROE is +1.98%, compared to CPRX's ROE of +0.27%. Regarding short-term risk, IVA is less volatile compared to CPRX. This indicates potentially lower risk in terms of short-term price fluctuations for IVA.Check CPRX's competition here
IVA vs ARWR Comparison August 2025
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 190.8M. In comparison, ARWR has a market cap of 2.5B. Regarding current trading prices, IVA is priced at $3.67, while ARWR trades at $17.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.02, whereas ARWR's P/E ratio is -14.83. In terms of profitability, IVA's ROE is +1.98%, compared to ARWR's ROE of -0.41%. Regarding short-term risk, IVA is less volatile compared to ARWR. This indicates potentially lower risk in terms of short-term price fluctuations for IVA.Check ARWR's competition here
IVA vs KNSA Comparison August 2025
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 190.8M. In comparison, KNSA has a market cap of 2.4B. Regarding current trading prices, IVA is priced at $3.67, while KNSA trades at $32.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.02, whereas KNSA's P/E ratio is 655.60. In terms of profitability, IVA's ROE is +1.98%, compared to KNSA's ROE of +0.01%. Regarding short-term risk, IVA is more volatile compared to KNSA. This indicates potentially higher risk in terms of short-term price fluctuations for IVA.Check KNSA's competition here
IVA vs PRVB Comparison August 2025
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 190.8M. In comparison, PRVB has a market cap of 2.4B. Regarding current trading prices, IVA is priced at $3.67, while PRVB trades at $24.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.02, whereas PRVB's P/E ratio is -16.43. In terms of profitability, IVA's ROE is +1.98%, compared to PRVB's ROE of +1.33%. Regarding short-term risk, IVA is more volatile compared to PRVB. This indicates potentially higher risk in terms of short-term price fluctuations for IVA.Check PRVB's competition here
IVA vs BLTE Comparison August 2025
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 190.8M. In comparison, BLTE has a market cap of 2.4B. Regarding current trading prices, IVA is priced at $3.67, while BLTE trades at $72.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.02, whereas BLTE's P/E ratio is -46.92. In terms of profitability, IVA's ROE is +1.98%, compared to BLTE's ROE of -0.37%. Regarding short-term risk, IVA is less volatile compared to BLTE. This indicates potentially lower risk in terms of short-term price fluctuations for IVA.Check BLTE's competition here
IVA vs LBPH Comparison August 2025
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 190.8M. In comparison, LBPH has a market cap of 2.3B. Regarding current trading prices, IVA is priced at $3.67, while LBPH trades at $59.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.02, whereas LBPH's P/E ratio is -26.66. In terms of profitability, IVA's ROE is +1.98%, compared to LBPH's ROE of -0.21%. Regarding short-term risk, IVA is more volatile compared to LBPH. This indicates potentially higher risk in terms of short-term price fluctuations for IVA.Check LBPH's competition here
IVA vs IBRX Comparison August 2025
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 190.8M. In comparison, IBRX has a market cap of 2.3B. Regarding current trading prices, IVA is priced at $3.67, while IBRX trades at $2.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.02, whereas IBRX's P/E ratio is -5.15. In terms of profitability, IVA's ROE is +1.98%, compared to IBRX's ROE of +0.61%. Regarding short-term risk, IVA and IBRX have similar daily volatility (3.61).Check IBRX's competition here
IVA vs RXRX Comparison August 2025
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 190.8M. In comparison, RXRX has a market cap of 2.3B. Regarding current trading prices, IVA is priced at $3.67, while RXRX trades at $5.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.02, whereas RXRX's P/E ratio is -2.99. In terms of profitability, IVA's ROE is +1.98%, compared to RXRX's ROE of -0.76%. Regarding short-term risk, IVA is less volatile compared to RXRX. This indicates potentially lower risk in terms of short-term price fluctuations for IVA.Check RXRX's competition here
IVA vs CNTA Comparison August 2025
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 190.8M. In comparison, CNTA has a market cap of 2.3B. Regarding current trading prices, IVA is priced at $3.67, while CNTA trades at $17.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.02, whereas CNTA's P/E ratio is -9.10. In terms of profitability, IVA's ROE is +1.98%, compared to CNTA's ROE of -0.57%. Regarding short-term risk, IVA is less volatile compared to CNTA. This indicates potentially lower risk in terms of short-term price fluctuations for IVA.Check CNTA's competition here
IVA vs DICE Comparison August 2025
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 190.8M. In comparison, DICE has a market cap of 2.3B. Regarding current trading prices, IVA is priced at $3.67, while DICE trades at $47.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.02, whereas DICE's P/E ratio is -21.91. In terms of profitability, IVA's ROE is +1.98%, compared to DICE's ROE of +0.56%. Regarding short-term risk, IVA is more volatile compared to DICE. This indicates potentially higher risk in terms of short-term price fluctuations for IVA.Check DICE's competition here
IVA vs VCYT Comparison August 2025
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 190.8M. In comparison, VCYT has a market cap of 2.3B. Regarding current trading prices, IVA is priced at $3.67, while VCYT trades at $28.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.02, whereas VCYT's P/E ratio is 84.62. In terms of profitability, IVA's ROE is +1.98%, compared to VCYT's ROE of +0.02%. Regarding short-term risk, IVA is more volatile compared to VCYT. This indicates potentially higher risk in terms of short-term price fluctuations for IVA.Check VCYT's competition here
IVA vs APGE Comparison August 2025
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 190.8M. In comparison, APGE has a market cap of 2.2B. Regarding current trading prices, IVA is priced at $3.67, while APGE trades at $36.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.02, whereas APGE's P/E ratio is -8.86. In terms of profitability, IVA's ROE is +1.98%, compared to APGE's ROE of -0.23%. Regarding short-term risk, IVA is less volatile compared to APGE. This indicates potentially lower risk in terms of short-term price fluctuations for IVA.Check APGE's competition here
IVA vs OCUL Comparison August 2025
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 190.8M. In comparison, OCUL has a market cap of 2.2B. Regarding current trading prices, IVA is priced at $3.67, while OCUL trades at $12.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.02, whereas OCUL's P/E ratio is -9.90. In terms of profitability, IVA's ROE is +1.98%, compared to OCUL's ROE of -0.70%. Regarding short-term risk, IVA is less volatile compared to OCUL. This indicates potentially lower risk in terms of short-term price fluctuations for IVA.Check OCUL's competition here
IVA vs TARS Comparison August 2025
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 190.8M. In comparison, TARS has a market cap of 2.2B. Regarding current trading prices, IVA is priced at $3.67, while TARS trades at $51.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.02, whereas TARS's P/E ratio is -22.43. In terms of profitability, IVA's ROE is +1.98%, compared to TARS's ROE of -0.32%. Regarding short-term risk, IVA is less volatile compared to TARS. This indicates potentially lower risk in terms of short-term price fluctuations for IVA.Check TARS's competition here
IVA vs FOLD Comparison August 2025
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 190.8M. In comparison, FOLD has a market cap of 2.2B. Regarding current trading prices, IVA is priced at $3.67, while FOLD trades at $6.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.02, whereas FOLD's P/E ratio is -58.17. In terms of profitability, IVA's ROE is +1.98%, compared to FOLD's ROE of -0.20%. Regarding short-term risk, IVA is less volatile compared to FOLD. This indicates potentially lower risk in terms of short-term price fluctuations for IVA.Check FOLD's competition here
IVA vs CALT Comparison August 2025
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 190.8M. In comparison, CALT has a market cap of 2.1B. Regarding current trading prices, IVA is priced at $3.67, while CALT trades at $40.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.02, whereas CALT's P/E ratio is -22.73. In terms of profitability, IVA's ROE is +1.98%, compared to CALT's ROE of -1.67%. Regarding short-term risk, IVA is less volatile compared to CALT. This indicates potentially lower risk in terms of short-term price fluctuations for IVA.Check CALT's competition here
IVA vs GLPG Comparison August 2025
IVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IVA stands at 190.8M. In comparison, GLPG has a market cap of 2.1B. Regarding current trading prices, IVA is priced at $3.67, while GLPG trades at $31.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IVA currently has a P/E ratio of -1.02, whereas GLPG's P/E ratio is -6.20. In terms of profitability, IVA's ROE is +1.98%, compared to GLPG's ROE of -0.10%. Regarding short-term risk, IVA is more volatile compared to GLPG. This indicates potentially higher risk in terms of short-term price fluctuations for IVA.Check GLPG's competition here